Table 2.
Results of Logistic Regression Analysis on Diagnostic Performance of the 9 Individual Markers and the Optimal Marker Panel
| Methylation Marker | ASCL1 | GHSR | SST | ST6GALNAC3 | ST6GALNAC5 | WDR17 | ZIC1 | ZNF582 | ZNF583 | Marker Panel |
|---|---|---|---|---|---|---|---|---|---|---|
| nonCV AUC | 0.89 | 0.79 | 0.87 | 0.79 | 0.84 | 0.85 | 0.87 | 0.91 | 0.80 | 0.93 |
| LOOCV AUC | 0.87 | 0.77 | 0.86 | 0.73 | 0.83 | 0.82 | 0.85 | 0.89 | 0.67 | 0.90 |
| Sensitivity | 0.76 | 0.76 | 0.76 | 0.60 | 0.78 | 0.66 | 0.84 | 0.78 | 0.68 | 0.82 |
| Specificity | 0.91 | 0.75 | 0.88 | 0.95 | 0.85 | 0.95 | 0.86 | 0.93 | 0.91 | 0.91 |
Reported are nonCV and LOOCV AUC. Sensitivity and specificity from LOOCV for the optimum threshold per marker and marker panel (ASCL1, ST6GALNAC3, WDR17, ZIC1, and ZNF582) are based on LASSO. Endpoint: AIN3 and anal SCC (AIN3+) in anal tissue samples of HIV+ men.
Abbreviations: AIN, anal intraepithelial neoplasia (grades 1–3); AUC, area under the curve; HIV+, human immunodeficiency virus positive; LOOCV, leave-one-out cross-validation; nonCV, non–cross-validated; SCC, anal squamous cell carcinoma.